ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

RBD1119

A development code.

Its studies are mostly in Coronary Artery Disease, led by Suzhou Ribo Life Science.

Furthest: phase 2, since Oct 13, 20262 company-led studies, 2 open or runningNext primary completion: Sep 30, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Suzhou Ribo Life Science22 open or runningphase 2since Oct 13, 2026Jun 13, 2025Sep 30, 2027phase 2 · NCT07884136

Also a collaborator on its studies: Fortrea.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 13, 2025First study: phase 1 study in Healthy VolunteersFirst studyNCT07042594 · 32 enrolled · Australia
  2. Oct 13, 2026Phase 2 study in Stable Coronary Artery DiseasePhase 2 reachedNCT07884136 · 200 planned · Poland, Sweden

Ahead

  1. Sep 30, 2027Primary completion: phase 2 study in Stable Coronary Artery DiseaseNCT07884136

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07884136Stable Coronary Artery Disease · Poland, Sweden2Not yet recruitingSep 30, 2027200
NCT07042594Healthy Volunteers · Australia1Active, not recruitingAug 5, 202632

How it is read

Names in the registry

  • “RBD1119”, 2 entries

Codes read as this program: RBD1119.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.